Serina Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Serina Therapeutics, Inc. on July 23, 2026, covering events occurring on July 19, 2026. The filing discloses the execution of an Amended and Restated Employment Agreement with the Company's Chief Executive Officer, Steve Ledger.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on executive compensation arrangements.
Material Changes
The primary material change is the amendment of the CEO's employment terms effective July 19, 2026. Key compensation updates include:
- Base Salary: Set at $500,000 annually.
- Annual Bonus: Target bonus equal to 50% of base salary ($250,000), contingent on Board-established goals.
- Equity: Acknowledges previously granted options and maintains eligibility for future awards at the Board's discretion.
Outlook, Risks, and Contingencies
The agreement outlines specific severance contingencies based on the reason for termination:
- Termination without Cause or Resignation for Good Reason (Standard): Entitles the CEO to 12 months of base salary, a pro-rated bonus, and 12 months of COBRA reimbursement.
- Termination in Connection with a Change in Control: Entitles the CEO to 1.5x base salary, 1.5x target bonus, a pro-rated bonus, 18 months of COBRA reimbursement, and full acceleration of unvested time-based equity awards.
- Death or Disability: Entitles the CEO (or estate) to accrued amounts, a pro-rated bonus, and 12 months of COBRA reimbursement.
- Restrictions: Includes a two-year non-compete and 18-month non-solicitation/no-hire covenants post-termination.
- Tax Provisions: Parachute payments are subject to a "best-net" reduction with no excise tax gross-up.
Investor Verification Checklist
- Verify the full text of the Amended and Restated Employment Agreement filed as Exhibit 10.1.
- Confirm the specific definitions of "Cause," "Good Reason," and "Change in Control" within the agreement.
- Review the Company's current cash position to assess the ability to fund potential severance obligations.
- Check for any subsequent filings regarding the vesting schedule of the CEO's existing equity awards.